The science behind every compound.

Comprehensive review showing consistent acceleration of repair timelines and significant effects on collagen formation.

BPC-157 counteracted NSAID-induced gastrointestinal lesions and maintained mucosal integrity.

Enhanced angiogenesis at injury sites, correlating with faster tissue repair.

Broad cytoprotective effects across organ systems including GI tract, liver, brain, and cardiovascular system.

Promoted cardiac cell migration and survival, reduced scar formation.

Accelerated wound healing through enhanced cell migration and angiogenesis.

Accelerated corneal wound healing.

Increased GH 2-10 fold and IGF-1 36-69% with sustained elevation.

Increased GH pulse amplitude without disrupting normal pulsatile patterns.

Selectively released GH with minimal effect on cortisol, prolactin, and ACTH.

Confirmed selectivity for GH release without cortisol stimulation.

Modulates 4,000+ genes, increased collagen production by ~70%.

Resets gene expression in aged tissue toward younger profiles.

Comprehensive review of wound healing including angiogenesis and nerve growth.

Improved physical performance and muscle homeostasis in aged mice.

Landmark paper. Regulated metabolic homeostasis through AMPK activation.

Enhanced exercise capacity and metabolic markers.

Activated telomerase, elongated telomeres, extended replicative lifespan.

Stimulated hTERT expression for telomere maintenance.

Significant HbA1c reduction and weight loss through triple receptor agonism.

24.2% mean body weight reduction at 48 weeks.

Superior weight loss across all dose levels with manageable GI adverse events.

5,246 men — TRT did not increase major adverse cardiovascular events.

Average gain of 1.6kg lean mass and loss of 2kg fat mass.

Significantly improved depression scores comparable to antidepressants.

Increased lean body mass 8.8%, decreased body fat 14.4%.

Comprehensive review of GH replacement effects on body composition, bone density, cardiovascular markers.

NIA ITP: extended median lifespan 9-14% in males, 13-26% in females.

Improved immune response to influenza vaccination by ~20%.

Improved cardiac function in companion dogs.

180,000+ patients — metformin users had 15% lower all-cause mortality than controls.

Scientific rationale for the TAME trial — AMPK activation, mTOR inhibition.

First FDA-approved trial testing whether a drug can slow human aging. 3,000 participants aged 65-79.

250mg/day increased muscle insulin sensitivity.

Improved insulin sensitivity, lipid profiles, physical activity in mice.

NAD+ decline as central aging feature, NMN as viable intervention.

Reduced cardiovascular mortality 43%, all-cause mortality 42%.

Improved endothelial function and reduced blood pressure.

Activated CREB/PGC-1alpha, increased mitochondrial number.

20mg/day improved attention, processing speed, working memory.

MIT: elevated brain magnesium, enhanced synaptic plasticity and memory.

Improved executive function, working memory, attention in older adults.

2.4mg weekly produced 14.9% mean body weight reduction vs 2.4% placebo over 68 weeks.

Reduced major adverse cardiovascular events by 26% in type 2 diabetes patients.

Sustained 15.2% weight loss over 104 weeks with improvements in cardiometabolic risk factors.

Participants lost up to 22.5% of body weight at highest dose over 72 weeks.

Superior HbA1c and weight reduction compared to semaglutide 1mg across all doses.

Greater glycemic control and 7-12kg weight loss vs insulin-associated weight gain.

Restored physiological GH secretion patterns with improved body composition and sleep quality.

GHRH analog increased slow-wave sleep duration and nocturnal GH release in older adults.

Significantly increased sexual desire and reduced distress in premenopausal women.

FDA-approved melanocortin receptor agonist acting centrally on sexual arousal pathways.

Demonstrated anxiolytic effects comparable to benzodiazepines without sedation or dependence.

Modulated IL-6 and BDNF expression, linking anxiolytic effects to immune and neurotrophic pathways.

Increased BDNF levels in hippocampus with significant improvements in learning and memory tasks.

Reduced infarct volume by 25-30% when administered acutely, through neurotrophic factor modulation.

10 million times more potent than BDNF at forming new synaptic connections in animal models.

Restored cognitive function in scopolamine-induced dementia through HGF/c-Met signaling.

Increased GH and IGF-1 levels, reversed diet-induced nitrogen wasting in healthy volunteers.

Daily oral dosing increased GH and IGF-1 to youthful levels without serious adverse effects.

Increased stage IV sleep duration by 50% and REM sleep by 20%.

Enhanced T-cell and dendritic cell function, improved outcomes in hepatitis B and immunocompromised patients.

Significantly improved seroconversion rates in hemodialysis patients who failed standard vaccination.

Stimulated lipolysis and inhibited lipogenesis without affecting IGF-1 or insulin levels.

Reduced body fat in obese Zucker rats via enhanced beta-oxidation without musculoskeletal side effects.

KPV entered epithelial cells and inhibited NF-kB activation, reducing inflammatory cytokines by 40-60%.

Oral KPV nanoparticles significantly reduced colitis severity and inflammatory markers in vivo.

Improved left ventricular function and reduced heart failure biomarkers via cardiolipin stabilization.

Restored mitochondrial energetics and reduced oxidative stress in aged muscle within one hour of treatment.

Improved 6-minute walk distance and quality of life in patients with mitochondrial cardiomyopathy.

NAD+ precursors rejuvenated muscle stem cells and extended lifespan in aged mice.

Oral NAD+ precursor increased blood NAD+ levels by 60% with favorable safety profile.

Comprehensive review establishing NAD+ decline as a hallmark of aging across tissues.

Upregulated genes involved in collagen synthesis, nerve growth, and anti-inflammatory pathways.

Free GHK showed tissue repair capacity independent of copper binding through direct gene modulation.

Reduced cartilage loss and improved joint pain scores vs placebo over 26 weeks.

Demonstrated chondroprotective and anti-inflammatory properties with improvements in MRI-measured cartilage volume.